IRIS
MOIA, RICCARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 669
NA - Nord America 423
AS - Asia 98
AF - Africa 1
Totale 1.191
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 419
IE - Irlanda 272
IT - Italia 155
SE - Svezia 123
DE - Germania 71
HK - Hong Kong 42
IN - India 36
UA - Ucraina 27
CN - Cina 12
FI - Finlandia 8
FR - Francia 8
IR - Iran 5
CA - Canada 4
AL - Albania 2
KR - Corea 2
DK - Danimarca 1
GB - Regno Unito 1
NG - Nigeria 1
NL - Olanda 1
TR - Turchia 1
Totale 1.191
Salva come PNG Salva come JPEG
Città #
Dublin 270
Chandler 61
Jacksonville 56
Hong Kong 42
Lawrence 31
Piemonte 31
Princeton 31
Bremen 23
Grafing 18
Novara 16
Wilmington 16
San Mateo 12
Beijing 10
Cassano Magnago 8
Helsinki 8
Turin 8
Ann Arbor 6
Boardman 6
Houston 6
Menlo Park 6
Milan 6
Strasbourg 6
West Jordan 6
Augusta 5
Berlin 5
Gunzenhausen 5
Somaglia 4
Andover 3
Elmas 3
Leawood 3
Naples 3
Palermo 3
Toronto 3
Areannamkwaengi 2
Ashburn 2
Castel Gandolfo 2
Cornedo Vicentino 2
Evansville 2
Foligno 2
Guangzhou 2
Mumbai 2
Opera 2
Parma 2
Perugia 2
Redwood City 2
Rimini 2
Sacramento 2
San Mauro Torinese 2
Tirana 2
Viterbo 2
Altavilla Monferrato 1
Ardabil 1
Biella 1
Buffalo 1
Cambridge 1
Dallas 1
Fairfield 1
Fremont 1
Gattico 1
Hyderabad 1
Invorio 1
Kocaeli 1
Magreglio 1
Monmouth Junction 1
Monza 1
Mülheim 1
Norwalk 1
Roasio 1
Ronciglione 1
Trani 1
Trecate 1
Winnipeg 1
Totale 776
Salva come PNG Salva come JPEG
Nome #
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia 62
Targeting p53 in chronic lymphocytic leukemia 58
-Active AKT signaling triggers CLL towards Richter's transformation via over-activation of Notch1 56
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity 53
An update on: molecular genetics of high-risk chronic lymphocytic leukemia 52
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 50
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 49
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome 47
Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment 47
Precision medicine management of chronic lymphocytic leukemia 45
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression 44
Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms 44
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations 40
An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient 40
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma 36
High reproducibility of spleen stiffness measurement by vibration-controlled transient elastography with a spleen-dedicated module 34
Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome 32
Druggable Molecular Pathways in Chronic Lymphocytic Leukemia 31
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 30
Reply to Aron P. Kater et al 29
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 29
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 28
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 26
Cerebrospinal fluid xanthochromia after pegasparaginase hepatotoxicity in B-cell acute lymphoblastic leukemia 26
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients 26
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 26
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 24
The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications 24
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 23
A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation 23
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 21
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 21
Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia 17
Liquid biopsy in hematological malignancies: current and future applications 16
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib 9
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 9
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 7
HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma 5
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia 5
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 4
High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy 3
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 2
Totale 1.253
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.108
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.108
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202087 0 0 0 0 0 0 6 2 6 57 15 1
2020/2021116 11 2 11 1 17 8 13 1 19 17 16 0
2021/2022228 2 4 10 9 19 3 23 3 5 23 60 67
2022/2023603 41 30 48 9 36 43 30 30 263 6 50 17
2023/2024219 27 28 31 11 41 11 46 4 1 17 2 0
Totale 1.253